lung
transplant
patient
vulner
group
immunosuppress
patient
prone
frequent
respiratori
infect
studi
episod
respiratori
symptom
lung
transplant
patient
almost
half
episod
unknown
infecti
etiolog
despit
extens
routin
diagnost
test
reanalyz
respiratori
sampl
episod
undetermin
etiolog
order
detect
potenti
viral
pathogen
missednot
account
routin
diagnost
respiratori
sampl
enrich
virus
filtrat
nucleas
digest
whole
nucleic
acid
extract
randomli
amplifi
high
throughput
metagenom
viru
sequenc
virus
identifi
bioinformat
pipelin
confirm
quantifi
use
specif
realtim
pcr
complet
routin
diagnost
identifi
confirm
viral
etiolog
infect
metagenom
approach
four
patient
three
rhinoviru
one
rhinoviru
b
infect
despit
initi
neg
result
specif
multiplex
pcr
notabl
major
sampl
also
posit
torqu
teno
viru
ttv
human
herpesviru
ttv
viral
load
increas
immunosuppress
throat
swab
blood
plo
one
http
doi
posttranspl
immunosuppress
significantli
increas
risk
viral
infect
lung
transplant
recipi
infect
commonli
consid
caus
mild
selflimit
diseas
immunocompet
host
lead
unusu
present
increas
sever
mortal
durat
numer
communityacquir
respiratori
viral
infect
implic
trigger
reject
episod
consequ
lung
transplant
recipi
frequent
test
rang
common
respiratori
virus
bacteria
fungi
despit
rigor
test
consider
number
episod
respiratori
symptom
remain
unresolv
success
diagnosi
would
howev
import
sever
reason
specif
treatment
avail
bacteri
fungal
pathogen
virus
rapid
confirm
reduc
unnecessari
diagnost
step
allow
set
effect
measur
restrict
nosocomi
transmiss
exclud
potenti
transmiss
pathogen
sourc
etiolog
therefor
equal
import
confirm
transplant
center
employ
tight
monitor
clinic
sign
respiratori
infect
lung
transplant
patient
prolong
period
transplant
panel
routin
assess
respiratori
virus
continu
expand
recent
year
current
mani
program
use
multiplex
pcr
analysi
target
differ
virus
howev
still
virus
potenti
relev
lung
transplant
set
includ
consid
high
incid
airway
inflamm
follow
lung
transplant
close
monitor
virom
may
advantag
link
distinct
pathogen
signatur
specif
outcom
allograft
dysfunct
rise
highthroughput
sequenc
also
call
next
gener
sequenc
combin
virussequ
independ
amplif
random
pcr
allow
unbias
detect
virtual
pathogen
present
given
sampl
methodolog
may
overcom
one
great
limit
routin
viru
diagnost
restrict
number
detect
pathogen
one
includ
assay
establish
use
approach
reanalyz
respiratori
sampl
lung
transplant
patient
present
symptom
suggest
airway
infect
viral
microbi
etiolog
found
extens
routin
diagnost
method
aim
resolv
viral
etiolog
infect
use
metagenom
sequenc
http
decontamin
read
bacteri
bovin
canin
origin
default
save
pipelin
could
reconstruct
made
avail
upon
specif
request
interest
research
reader
contact
correspond
author
michael
huber
huber
michael
virologyuzhch
vulner
popul
donor
next
kin
provid
written
inform
consent
freeli
given
studi
perform
univers
hospit
zurich
switzerland
bed
tertiari
care
teach
hospit
cover
medic
specialti
except
pediatr
orthoped
sinc
may
patient
list
lung
transplant
patient
prior
lung
transplant
ask
particip
current
studi
inclus
criteria
age
least
year
written
inform
consent
willing
particip
studi
notabl
ask
individu
consent
lung
transplant
recipi
either
includ
time
transplant
baselin
enrol
time
present
symptom
suggest
airway
infect
indic
enrol
particip
enrol
baselin
plan
studi
visit
time
transplant
week
year
thereaft
drop
rate
low
addit
visit
schedul
patient
develop
symptom
suggest
airway
infect
everi
indic
enrol
symptom
visit
followup
visit
schedul
visit
throat
swab
plasma
urin
stool
sampl
obtain
patient
evalu
sign
infect
relev
transplant
outcom
event
airway
infect
consid
cough
andor
dyspnea
andor
decreas
forc
expiratori
volum
second
present
ml
decreas
fever
alon
consid
suffici
defin
airway
infect
healthi
donor
recruit
univers
zurich
question
comorbid
throat
swab
obtain
lung
transplant
recipi
induct
immunosuppress
consist
basiliximab
mg
day
surgeri
postop
day
methylprednisolon
g
given
oper
procedur
mg
postop
day
mainten
immunosuppress
includ
mycophenol
mofetil
prednison
calcineurin
inhibitor
primarili
cyclosporin
lung
transplant
recipi
receiv
antibacteri
antifung
prophylaxi
sulfamethoxazol
trimethoprim
itraconazol
aerosol
amphotericin
b
antivir
prophylaxi
administ
base
cmvrisk
constel
depend
serolog
donor
recipi
intermedi
donor
cmv
neg
positiverecipi
cmv
posit
high
risk
donor
positiverecipi
neg
constel
valganciclovir
use
wherea
low
risk
constel
donor
cmv
negativerecipi
cmv
neg
valaciclovir
prophylaxi
hsv
vzv
administ
prophylact
regimen
usual
prescrib
lifelong
routin
workup
includ
throat
swab
bronchoalveolar
lavag
bal
viral
microbi
analysi
respiratori
virus
test
use
respiratori
pathogen
panel
bocaviru
mycoplasma
pneumonia
cmv
ebv
test
blood
sampl
use
specif
pcr
routin
cultur
bacteria
fungi
perform
sampl
sent
microbiolog
laboratori
throat
swab
sampl
collect
ml
viru
transport
medium
hepe
buffer
ph
fc
antibiot
bal
sampl
collect
nativ
enrich
free
viru
particl
sampl
centrifug
rpm
min
supernat
filter
filter
total
nucleic
acid
extract
filtrat
nuclisen
easymag
craponn
franc
elut
volum
rna
dna
amplifi
two
separ
workflow
rna
amplif
random
primer
anchor
sequenc
atcgtcgtcgtaggctgctcnnnnnnnn
use
revers
transcript
superscript
iii
invitrogenthermo
fisher
waltham
eluat
perform
min
dna
workflow
eluat
incub
random
primer
rna
workflow
min
cool
min
one
round
secondstrand
synthesi
larg
klenow
fragment
new
england
biolab
ipswich
enzym
per
reaction
perform
workflow
min
follow
inactiv
min
workflow
nucleic
acid
amplifi
amplitaq
gold
appli
biosystemsthermo
fisher
use
anchor
primer
follow
temperatur
protocol
min
cycl
min
min
final
workflow
pool
equal
amount
librari
construct
nexteraxt
illumina
san
diego
ca
prior
sequenc
bp
illumina
miseq
version
reagent
fastq
workflow
sampl
demultiplex
use
miseq
report
whole
sequenc
procedur
took
work
day
read
analyz
use
virmet
inhous
bioinformat
pipelin
briefli
read
qualityfilt
clean
nonvir
read
align
star
human
bacteri
bovin
canin
genom
remain
read
align
blast
inhous
viral
databas
contain
complet
viral
sequenc
blast
hit
lowest
evalu
report
given
ident
higher
sequenc
bioinformat
analysi
done
duplic
sampl
result
merg
analysi
viral
read
undetermin
read
sampl
upload
zenodo
http
confirm
identifi
viru
hit
denovo
contig
assembl
velvet
minimum
contig
length
use
viru
specif
read
report
virmet
pipelin
analyz
blast
enterovirus
genotyp
autom
genotyp
tool
rhinoviru
ttv
detect
specif
realtim
pcr
describ
ttv
calcul
use
plasmidbas
standard
known
concentr
everi
run
total
lung
transplant
recipi
particip
studi
tabl
among
patient
enrol
baselin
show
respiratori
symptom
month
lung
transplant
wherea
patient
develop
respiratori
symptom
among
addit
patient
indic
enrol
observ
total
episod
respiratori
symptom
fig
viral
bacteri
etiolog
establish
routin
test
episod
respect
note
episod
microbi
viral
etiolog
infect
could
determin
routin
diagnost
fig
cmv
ebv
viral
load
test
frequent
blood
neg
investig
respiratori
episod
particularli
interest
episod
respiratori
infect
differ
patient
consid
unknown
etiolog
despit
typic
symptom
sequenc
throat
swab
bal
sampl
use
highthroughput
metagenom
analysi
tabl
tabl
identifi
read
common
respiratori
virus
like
rhinoviru
b
hrvab
human
coronaviru
cov
five
sampl
confirm
correct
identif
virus
metagenom
pipelin
perform
denovo
assembl
specif
viru
read
use
blast
align
result
contig
full
ncbi
databas
four
case
rhinoviru
detect
contig
assembl
genotyp
expect
correspond
human
rhinoviru
b
respect
denovo
align
done
small
number
read
direct
blast
analysi
read
produc
match
human
coronaviru
genom
next
frequent
record
refer
sequenc
report
pipelin
use
analyz
genom
coverag
although
promin
spike
coverag
sampl
read
distribut
sever
locat
genom
give
confid
read
origin
sequenc
fulllength
viru
contamin
misalign
fig
especi
import
verifi
sampl
patient
account
cov
read
airway
infect
red
diarrhea
yellow
fever
blue
symptom
includ
dyspnea
decreas
purpl
death
patient
black
http
use
specif
pcr
confirm
result
five
case
rhinoviru
coronaviru
infect
detect
metagenom
analysi
five
patient
previous
check
multiplex
pcr
presenc
respiratori
virus
routin
test
diagnos
neg
first
reexamin
origin
diagnost
test
result
two
case
late
amplif
multiplex
pcr
evid
howev
fulfil
criteria
posit
eg
reach
plateau
cycl
therefor
report
neg
patient
cov
detect
metagenom
sequenc
respiratori
viru
diagnost
perform
analyz
symptom
visit
test
conduct
day
prior
symptom
visit
howev
show
evid
late
cov
amplif
fulfil
criteria
posit
reanalysi
sampl
symptom
visit
confirm
result
metagenom
analysi
show
clear
posit
cov
hku
ct
next
conduct
specif
pcr
rhinoviru
use
simplex
assay
confirm
high
viral
load
rhinoviru
infect
patient
ct
valu
patient
ct
valu
investig
sampl
patient
show
low
rhinoviru
infect
ct
valu
read
detect
sequenc
contrast
rhinoviru
could
detect
pcr
patient
read
detect
tabl
addit
common
respiratori
virus
report
frequent
identifi
read
human
herp
viru
torqu
teno
viru
ttv
sampl
respect
tabl
ttv
read
analyz
depth
differ
type
cross
contamin
sampl
ttv
sequenc
sampl
sequenc
run
detect
tabl
identifi
read
human
virus
includ
ki
polyomaviru
human
papillomaviru
human
herpesviru
individu
sampl
tabl
read
human
endogen
retroviru
explain
incomplet
filter
human
read
metagenom
pipelin
report
numer
read
bacteriophag
tabl
bacteriophag
identifi
primarili
infect
bacteria
known
colon
upper
respiratori
tract
ttv
andor
read
prove
preval
mani
sampl
expect
ttv
ubiquit
annelloviru
known
expand
immunosuppress
high
preval
respiratori
tract
sampl
surpris
specif
realtim
pcr
confirm
case
ttv
identifi
metagenom
sequenc
also
identifi
addit
case
pick
metagenom
analysi
tabl
viral
load
level
low
across
sampl
limit
chanc
detect
sequenc
assess
whether
presenc
virus
link
either
immunosuppress
respiratori
infect
measur
ttv
level
avail
throat
swab
blood
sampl
studi
particip
throat
swab
healthi
control
interestingli
detect
throat
swab
could
detect
blood
suggest
local
reactiv
viral
load
ttv
prove
similar
amongst
healthi
control
lung
transplant
recipi
baselin
fig
show
lung
transplant
recipi
higher
viral
load
time
transplant
similarli
see
differ
ttv
viru
load
symptomat
visit
symptomfre
visit
enrol
scenario
fig
next
stratifi
patient
two
group
base
whether
patient
develop
respiratori
symptom
month
transplant
monitor
viral
load
ttv
longitudin
two
patient
group
shown
previou
studi
ttv
viral
load
swab
blood
significantli
increas
immunosuppress
plateau
first
routin
visit
patient
group
studi
fig
importantli
though
observ
signific
differ
viral
load
symptomfre
symptomat
group
baselin
visit
closest
week
one
year
respect
follow
pattern
viral
load
remain
low
level
swab
throughout
observ
period
undetect
blood
fig
present
studi
use
metagenom
viru
sequenc
reanalyz
episod
suggest
airway
infect
lung
transplant
recipi
remain
neg
extens
routin
test
identifi
viral
infecti
etiolog
focus
virus
open
metagenom
approach
prove
success
identifi
differ
pathogen
five
sampl
success
detect
sequenc
read
respiratori
virus
account
prior
routin
test
rhinovirusspecif
simplex
assay
confirm
presenc
rhinoviru
three
four
sampl
previous
neg
result
routin
multiplex
diagnost
hrv
detect
metagenom
approach
sequenc
read
distribut
whole
genom
respect
virus
fig
highlight
inde
fulllength
genom
detect
despit
fact
three
five
detect
virus
seem
low
level
infect
indic
low
read
number
high
ct
valu
identifi
respiratori
virus
certainli
clinic
relev
infect
occur
patient
suffer
respiratori
symptom
despit
extens
routin
test
etiolog
found
importantli
metagenom
analysi
detect
viral
pathogen
sampl
prior
routin
multiplex
pcr
test
neg
later
confirmatori
simplex
pcr
though
posit
like
due
low
specif
pcr
given
viru
strain
occur
particularli
multiplex
assay
howev
primer
probe
sequenc
multiplex
pcr
assay
avail
difficult
ass
thu
metagenom
sequenc
certain
case
effect
routin
multiplex
pcr
gener
drawback
metagenom
analysi
remain
rel
low
sensit
compar
specif
simplex
pcr
inde
real
time
pcr
detect
ttv
viru
addit
sampl
compar
metagenom
sequenc
hand
detect
metagenom
techniqu
alway
correl
viru
abund
number
factor
influenc
amount
viru
given
sampl
locat
techniqu
sampl
preanalyt
sampl
prepar
great
impact
rel
amount
viral
genom
avail
sequenc
enrich
viral
nucleic
acid
clinic
sampl
prior
sequenc
success
impli
protocol
thu
crucial
metagenom
sequenc
frequent
detect
ttv
monitor
longitudin
dynam
ttv
pcr
show
increas
ttv
initi
immunosuppress
previous
describ
nevertheless
presenc
viru
could
link
relev
clinic
manifest
far
intriguingli
identifi
major
swab
sampl
unlik
ttv
show
dynam
remain
low
level
even
initi
immunosuppress
therapi
interestingli
restrict
respiratori
tract
detect
blood
local
presenc
intrigu
need
investig
detail
understand
signific
lung
transplant
recipi
owe
commonli
low
pathogen
clinic
manifest
diseas
poorli
describ
seropreval
human
popul
estim
primari
infect
viru
typic
occur
first
year
life
link
roseolalik
diseas
fever
cmv
diseas
secondari
reactiv
latent
reservoir
viru
take
place
solid
organ
transplant
patient
first
week
immunosuppress
therapi
frequent
combin
detect
cmv
data
cohort
suggest
replic
respiratori
tract
depend
cmv
replic
patient
either
intermedi
highrisk
constel
receiv
cmv
antivir
prophylaxi
valganciclovir
accordingli
cmv
detect
sampl
analyz
metagenom
sequenc
whether
medic
influenc
replic
remain
unknown
metagenom
approach
identifi
respiratori
virus
five
sampl
unknown
etiolog
remain
symptomat
lung
transplant
sampl
potenti
diseas
relat
virus
found
leav
exact
etiolog
symptom
unclear
whether
due
insuffici
sensit
metagenom
approach
novel
viru
detect
bioinformat
analysi
etiolog
viral
origin
remain
unknown
time
relev
metagenom
find
treat
physician
still
need
critic
evalu
reliabl
metagenom
analysi
must
provid
convinc
evid
identifi
viru
read
inde
indic
presenc
postul
virus
number
virusspecif
read
depth
coverag
percent
locat
genom
cover
main
part
inform
howev
appropri
threshold
establish
literatur
far
hand
sequenc
read
viru
genom
cover
sever
differ
locat
fig
provid
plausibl
indic
detect
read
inde
indic
presenc
postul
virus
nevertheless
care
evalu
confirm
necessari
treatment
decis
sole
base
ng
find
overal
studi
highlight
potenti
metagenom
viru
sequenc
complex
diagnost
situat
immunocompromis
host
open
metagenom
approach
use
addit
routin
test
panel
addit
effort
valid
result
interpret
need
fulli
incorpor
technolog
diagnost
repertoir
support
inform
